GFL’s FY27 Capex Targets INR 3,150 Crore, Battery Sales Scaling

Gujarat Fluorochemicals Limited (GFL) — Q4 FY26 Earnings Call (held 26 May 2026)

1. Overall Tone of Management: Optimistic

Management repeatedly emphasizes “constructive” long-term outlook and confidence in execution, with forward-looking statements like:
– “We remain constructive on the long-term outlook…”
– “We remain confident in our ability to deliver sustained growth…”
– “We remain pleased to share that all the initial capacities… have now been commissioned and contracted for.”

2. Key Themes from Management Commentary

• Macro volatility but disciplined execution: Management cites volatile global environment (tariffs uncertainty, geopolitics, logistics, commodity/currency volatility) but stresses “disciplined execution, operational excellence… stringent cost management.”
• Chemicals (core) resilience and growth: Q4 chemicals show strong YoY growth (revenue +11%, EBITDA +13%, PAT +5%), led by Fluoropolymers.
• Fluoropolymers growth + capex for new fluoropolymers:
• Fluoropolymers revenue growth: +19% YoY and +14% QoQ in Q4.
• Management says existing new-fluoropolymer capacities are nearing “optimum utilization,” prompting further capex.
• Fluorochemicals: R-32 milestone and ramp-up narrative:
• “commencement of R-32 production in March 2026” and R-32 capex of ~INR150 cr in FY27.
• Demand for refrigerants expected “healthy” (AC, refrigeration, cold chain, AI data centers).
• Battery materials: inflection point + commissioning/contracting progress:
• “all the initial capacities planned under phase one have now been commissioned and contracted for.”
• LiPF6 approvals mostly received; “commercial sales are scaling up.”
• LFP CAM qualification expected by end of Q3 FY27, then commercial supply.
• Natural graphite anode active material facility planned to increase integration (“nearly 70% of the value of an LFP battery cell”).
• Capex visibility:
• FY27 capex earmarked INR 3,150 cr (EV: INR 2,300 cr; GFL: INR 850 cr).
• Battery materials also references cumulative capex framework: “INR 6,000 crores cumulative capex by FY ’28” with targeted asset turns ~2x and EBITDA margins “over 25% plus.”

3. Q&A Analysis

Theme A: Capex allocation & product scope (Fluoropolymers, R-32, battery chemicals)

• Core questions
• Whether fluoropolymer expansion is PTFE vs new fluoropolymers, and how full-year fluoropolymer growth splits.
• R-32 expansion details: size, commissioning/ramp timing, further expansion beyond 20,000 tons.
• Battery capex breakdown and progress on approvals/technology (homegrown vs tie-ups).
• Management responses
• Fluoropolymers capex: “investment will be on new fluoropolymers”; no detailed split of growth by grade.
• R-32: 20,000 tons is the announced phase; production already started; ramp to 20,000 over time.
• Battery chemicals: approvals progress described by product:
  • LiPF6: approvals from major players; commercial sales scaling.
  • LFP CAM: sample qualified; final qualification expected by end of Q3; commercial supply after.
  • Technology: described as starting with salt/electrolyte, then cathode active material; no major external tie-up disclosed.
• Notable/partial/evasive elements
• No granular disclosure on fluoropolymer growth split by PTFE vs new grades.
• EV contract terms: management repeatedly avoids specifics (“not at liberty to give details of our contracts”).

Theme B: Battery materials revenue visibility, gestation, and “fully contracted” meaning

• Core questions
• When “fully booked/contracted” translates into FY27 revenue (take-or-pay vs soft commitment).
• Revenue potential and whether FY27 is a “qualification year” vs material supply.
• Explanation for EV segment losses spike (startup accounting/capitalization rules).
• Management responses
• “Fully contracted” applies to LiPF6 and LFP (and ramp depends on gestation/qualification).
• Revenue modeling: management uses asset turnover ~2x concept but refuses exact numbers due to gestation and utilization completion.
• FY27: material quantity for salt; LFP later (after Q3).
• Loss spike explanation: accounting treatment—once capitalized/operations start, pre-op expenses/trial losses stop capitalizing and flow through P&L; also mentions one-time FX impact tied to buyer’s credit and extreme USD/INR movement.
• Notable/strong answers
• EV accounting explanation was relatively concrete (capitalization date, P&L treatment, FX one-time loss).
• Evasive/partial
• Revenue guidance remains qualitative; management avoids giving a numeric FY27/FY28 battery revenue target despite repeated analyst prompts.

Theme C: Fluoropolymers utilization, “why capex now,” and margin sustainability

• Core questions
• Why capex is being added even if utilization is not at previously referenced “steady-state” levels.
• Whether EBITDA/margins are in line with earlier expectations or below.
• FY27 growth outlook: volume vs pricing; competitive price actions.
• Management responses
• Capex timing rationale: earlier capacities are nearing “optimal utilization”; higher-grade qualification has longer gestation; now approvals are coming through.
• Margin: management says no disconnect; EBITDA margins expected to continue improving with mix and value-added grades.
• FY27 growth: Kapil guided ~15%–20% growth in fluoropolymers; explicitly mentions both pricing and volume growth and cost push being balanced.
• Notable
• Management clarifies they never provided capacity utilization numbers earlier, reducing comparability with prior “steady-state” expectations.

Theme D: R-32 ramp-up, commissioning status, and quota/capacity beyond 20,000

• Core questions
• Whether R-32 is at optimal levels already; ramp timing in FY27.
• Plans to add capacity beyond 20,000 given quota availability.
• Clarification on timeline consistency (end-2026 vs end-2027 in earlier calls).
• Management responses
• R-32: production started; “already started operating from April onwards” and ramp continues.
• Beyond 20,000: management says they will add to quota as market dynamics allow; quota numbers are “very clear” internally.
• Notable
• Timeline consistency was addressed: earlier delays acknowledged; now management reiterates quota-based additions with time to decide later.

Theme E: Working capital and inventory days

• Core questions
• Inventory days rising: path back to historical levels (90–95 days).
• How working capital changes as battery scales.
• Why high warehouse inventory in Germany/US.
• Management responses
• Working capital cycle elevated due to:
  • Denominator effect from exceptional FY22/FY23 chemical price base.
  • Business model: stock-and-sell with depots/warehouses and long transit times.
  • EV ramp-up: additional raw material inventory and LiPF6 commercialization.
• Warehouse inventory rationale: “insurance stock” for JIT customers + increased voyage time (3–4 weeks to 7–8 weeks).
• Notable
• Provided a structured explanation tying inventory to transit time and customer JIT insurance.

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY27 capex: INR 3,150 crores
• EV (GFCL EV): INR 2,300 crores
• GFL (standalone): INR 850 crores
  • Refrigerant gas infrastructure: ~INR 150 crores
  • Electronic specialty chemicals (semiconductor): INR 222 crores
  • Fluoropolymer capacities: INR 250 crores
  • Backward integration + maintenance: INR 230 crores
• Battery materials capex (FY27): ~INR 2,300 crores across portfolio (including anode active material project).
• Cumulative battery materials capex target: INR 6,000 crores by FY28
• Fluoropolymers growth outlook (FY27): ~15% to 20% (management also notes pricing and volume both contributing).
• R-32 capacity: ramp to 20,000 tons (phase) and production already started; further additions to quota later.
• LFP CAM qualification timing: “expected by the end of the third quarter” (FY27), then commercial supply.

Implicit signals (qualitative)

• Battery materials: “inflection point,” “commissioned and contracted,” and expectation of quarter-on-quarter revenue growth with “significant” rise; management expects 3-digit battery revenue by end of FY27 (qualitative numeric range, but not fully specified).
• Chemicals: constructive demand outlook for refrigerants and stable/range-bound pricing for caustic soda and fluoromethane.
• EV contracts: management implies meaningful revenue visibility but avoids contract structure details (take-or-pay vs soft).

5. Standout Statements (direct / highly revealing)

• Battery commissioning & contracting: “all the initial capacities planned under phase one have now been commissioned and contracted for.”
• EV revenue scaling expectation: “we would still see a growth going up quarter-on-quarter… and we expect to reach… the 3- digit number by the end of this quarter…” (Rohit Nagraj question; management confirms).
• R-32 ramp status: “It’s already started operating from April onwards.”
• Capex clarity: “GFL has earmarked INR 3,150 crores of capex for FY ’27…”
• EV accounting explanation (loss spike): capitalization/operational accounting shift: “once we start the operations… all the expenses flows through P&L…”
• Working capital drivers: “voyage time has increased… to almost 7 to 8 weeks” and inventory acts as “insurance stock.”

6. Red Flags / Positive Signals

Red flags
– Limited revenue quantification for battery materials: despite “contracted” claims, management repeatedly avoids numeric FY27/FY28 revenue targets and contract structure (take-or-pay).
– “Constructive” language with ongoing volatility: management acknowledges macro disruption and volatility, but guidance remains mostly capex and qualitative demand statements.
– Potential narrative drift on timelines: R-32 commissioning/ramp has had multiple timeline references across calls; current call clarifies April optimal operations but earlier delays were acknowledged.

Positive signals
– Operational milestones achieved: R-32 production commenced; battery phase-one capacities commissioned; LiPF6 approvals largely received; LFP qualification timeline given.
– More concrete accounting transparency: EV loss spike explanation included capitalization date and FX one-time loss.
– Clear capex roadmap: detailed FY27 capex breakdown and cumulative capex framework.

7. Historical Comparison & Consistency Analysis (vs prior 3–4 calls)

a. Change in Tone Over Time

• Current (Q4 FY26): Optimistic
• Prior calls:
• Q3 FY26 (Feb 2026): “outlook… meaningfully more constructive” but still highlighted refrigerant headwinds and R-32 delay (“delay in R-32 production start-up resulted in lower-than-expected profitability”).
• Q2 FY26 (Nov 2025): optimistic on recovery; EV revenue expected from Q4; margins improving.
• Q1 FY26 (Aug 2025): confident on fluoropolymers growth and R-32 ramp; battery ramp described as medium-to-long term.
• Shift classification: More Optimistic
• What changed: management now emphasizes commissioning/contracting completion in battery materials and R-32 already operating from April, reducing “delay” uncertainty relative to Q3 FY26.

b. Tracking Past Commitments vs Outcomes (selected)

1. R-32 commissioning timeline
2. Past statement (Q3 FY26, Feb 12 2026): R-32 start-up delay; earlier expectation had been earlier in the year.
3. Current outcome: “commencement of R-32 production in March 2026” and “already started operating from April onwards.”

4. Flag: ✅ Delivered (with delay acknowledged vs earlier expectations)

5. Battery phase-one commissioning

6. Past statement (Q3 FY26, Feb 12 2026): LFP qualification progressing; binders qualification progressing; revenue ramp expected as qualifications complete.
7. Current outcome: “all the initial capacities planned under phase one have now been commissioned and contracted for.”

8. Flag: ✅ Delivered

9. Battery revenue ramp timing

10. Past statement (Q2 FY26, Nov 11 2025): “revenue is expected to start flowing in from Q4” and improve consolidated margins.
11. Current outcome: management now says LiPF6 commercial sales scaling; FY27 salt material quantity; LFP after Q3.

12. Flag: ✅/⏳ Partially delivered (LiPF6 ramp appears underway; LFP still qualification-gated)

13. Fluoropolymers growth guidance

14. Past statement (Aug 2025 / Nov 2025): ~25% growth expectation.
15. Current outcome: Q4 shows strong growth; FY27 guided 15%–20% (more conservative than earlier 25% narrative).
16. Flag: ⏳ Delayed / narrative moderated (not necessarily missed, but guidance range reduced)

c. Narrative Shifts

• Battery materials emphasis increased from “promising/qualification” to “commissioned/contracted.”
• Fluoropolymers narrative shifted from “approval pipeline/legacy exit” to “optimal utilization reached → new capex.”
• Refrigerant narrative shifted from “delay headwinds” to “R-32 ramp already operating” and demand “healthy.”
• Specialty chemicals / fluorospecialty is less emphasized in Q4 FY26 vs earlier calls where it was discussed as stable/subdued.

d. Consistency & Credibility Signals

• Credibility: Medium to High
• Strengths: operational milestones (commissioning/qualification) are now backed by timelines; EV loss spike accounting explanation was specific.
• Weakness: battery revenue quantification remains guarded; “contracted” claims are not translated into numeric revenue visibility, limiting external validation.

e. Evolution of Key Themes

• Demand/macro: improving “signs” but still volatility acknowledged.
• Margins: management claims stability/maintenance of EBITDA margins despite volatility; EV losses explained as startup accounting.
• Expansion: capex roadmap becomes more detailed and product-specific in FY27.
• Regulatory/tariffs: earlier calls focused heavily on US tariff uncertainty; current call mentions volatility but less on tariff mechanics, more on execution and ramp.

f. Additional Insights (cross-period intelligence)

• Risk is migrating from “qualification delays” to “utilization/working capital and ramp execution.”
  Battery is now commissioned, but management still leans on gestation and qualification gating for revenue timing.
• Guidance conservatism appears in fluoropolymers: earlier 25% growth framing softened to 15%–20% for FY27, suggesting either normalization of growth or more cautious demand assumptions.
• Working capital remains structurally elevated due to business model + transit times; management does not commit to returning to 90–95 days quickly, implying a persistent working-capital intensity.